#1 Clinical Trials Search in Europe

Cd7-Cart01

A new clinical trial is exploring the use of CD7-CART01, a innovative cell therapy, for treating children and young adults with relapsed or refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LL). This Phase I/II study aims to evaluate the safety and effectiveness of this chimeric antigen receptor (CAR) T-cell therapy in patients who have not responded well to standard treatments.

Table of Contents

What is CD7-CART01?

CD7-CART01 is a new type of cancer treatment being studied for children and young adults with certain types of leukemia and lymphoma. It belongs to a class of treatments called chimeric antigen receptor T-cell therapy (CAR-T therapy). This innovative approach uses the patient’s own immune cells, which are modified in a laboratory to better fight cancer.[1]

Target Conditions

CD7-CART01 is specifically designed to treat patients with relapsed or refractory CD7+ T-cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LL). Let’s break down what this means:

  • Relapsed: The cancer has returned after initial treatment.
  • Refractory: The cancer has not responded well to standard treatments.
  • CD7+: The cancer cells have a specific protein called CD7 on their surface.
  • T-cell Acute Lymphoblastic Leukemia/Lymphoma: A type of blood cancer that affects T-cells, which are important for the immune system.

This treatment is being studied for patients aged 6 months to 25 years who have not responded well to other treatments or whose cancer has come back.[1]

How CD7-CART01 Works

CD7-CART01 works by modifying the patient’s own T-cells (a type of immune cell) to recognize and attack cancer cells. Here’s a simple breakdown of the process:

  1. T-cells are collected from the patient’s blood.
  2. In a laboratory, these T-cells are genetically modified to produce special receptors called chimeric antigen receptors (CARs) that can recognize the CD7 protein on cancer cells.
  3. The modified T-cells (now called CAR-T cells) are grown in large numbers.
  4. The CAR-T cells are then infused back into the patient’s body, where they can find and destroy cancer cells that have the CD7 protein.

Clinical Trial Details

CD7-CART01 is currently being studied in a Phase I/II clinical trial. This means the study is designed to:

  • Phase I: Determine the safe dose of CD7-CART01 and understand any side effects.
  • Phase II: Test how well the treatment works at the dose determined in Phase I.

The main goals of this study are:[1]

  • To evaluate the safety of CD7-CART01 at different doses.
  • To determine how effective CD7-CART01 is in treating the cancer.
  • To measure how many patients achieve complete remission (no detectable cancer) after treatment.

Eligibility Criteria

Not all patients with T-ALL/LL are eligible for this study. Some key eligibility criteria include:[1]

  • Age: 6 months to 25 years old
  • Diagnosis of CD7+ T-ALL or lymphoblastic lymphoma that has relapsed or not responded to standard treatments
  • Adequate organ function (heart, liver, kidneys)
  • No active, severe infections
  • No active graft-versus-host disease (for patients who have had stem cell transplants)

There are additional specific medical criteria that doctors will use to determine if a patient is eligible for the study.

Treatment Process

The treatment with CD7-CART01 involves several steps:[1]

  1. Screening: Doctors will perform tests to ensure the patient is eligible for the treatment.
  2. T-cell collection: A process called apheresis is used to collect T-cells from the patient’s blood.
  3. CAR-T cell production: The collected T-cells are sent to a laboratory where they are modified and multiplied.
  4. Conditioning chemotherapy: Patients receive chemotherapy drugs (cyclophosphamide and fludarabine phosphate) to prepare their body for the CAR-T cells.
  5. CAR-T cell infusion: The modified CAR-T cells are infused back into the patient’s bloodstream.
  6. Monitoring: Patients are closely monitored for at least 28 days after the infusion to check for responses and side effects.

Potential Benefits

While the effectiveness of CD7-CART01 is still being studied, the potential benefits may include:[1]

  • Achieving complete remission (no detectable cancer)
  • Eliminating minimal residual disease (very low levels of cancer cells that remain after treatment)
  • Providing a treatment option for patients who have not responded to other therapies

Safety Considerations

As with any new treatment, there are potential risks and side effects. The clinical trial is designed to carefully monitor patients for:[1]

  • Cytokine release syndrome (a condition that can cause fever, low blood pressure, and breathing difficulties)
  • Neurological effects
  • Infections
  • Other unexpected side effects

Patients in the study will be closely monitored and treated for any side effects that may occur.

Aspect Details
Study Type Phase I/II, Non-Randomized, Single Group Assignment, Open Label
Condition Relapsed/refractory CD7+ T-cell Acute Lymphoblastic Leukemia/Lymphoma
Intervention CD7-CART01 (Chimeric Antigen Receptor-Expressing T cells)
Age Group 6 months – 25 years
Primary Objectives Evaluate safety, establish recommended dose, assess antitumor effect
Key Eligibility CD7 expressing T-ALL/LL, measurable disease, adequate organ function
Administration Intravenous infusion

FAQ

  • What is CD7-CART01? CD7-CART01 is a type of cell therapy where a patient's own T-cells are modified to express a chimeric antigen receptor (CAR) that targets CD7, a protein found on the surface of T-cell leukemia and lymphoma cells. This therapy is designed to help the patient's immune system fight against their cancer more effectively.
  • Who is eligible for this clinical trial? The trial is open to patients aged 6 months to 25 years with relapsed or refractory CD7-positive T-cell Acute Lymphoblastic Leukemia or Lymphoma. Eligible patients must have measurable disease and meet specific criteria regarding their disease status and previous treatments.
  • What are the main goals of this clinical trial? The primary goals are to evaluate the safety of CD7-CART01 at different doses, establish the recommended dose, and assess its effectiveness in achieving complete remission with minimal residual disease negativity at day 28 after infusion.
  • How is the treatment administered? CD7-CART01 is administered as a cell suspension for injection through intravenous infusion. Before receiving the therapy, patients undergo a process called apheresis to collect their T-cells, which are then modified to create the CD7-CART01 product.
  • What are some potential side effects or risks? While specific side effects are not detailed in the provided information, CAR T-cell therapies can have various risks including cytokine release syndrome, neurological effects, and infections. The trial includes careful monitoring for any dose-limiting toxicities in the first 28 days after infusion.

Ongoing Clinical Trials on Cd7-Cart01

  • Study of CD7-CART01, Cyclophosphamide, and Fludarabine Phosphate for Children and Young Adults with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

    Recruiting

    1 1 1
    Investigated drugs:
    Italy

Glossary

  • T-cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LL): A type of cancer that affects T-cells, which are a part of the immune system. It can occur in the blood and bone marrow (leukemia) or in lymph nodes and other tissues (lymphoma).
  • Chimeric Antigen Receptor (CAR) T-cell therapy: A type of treatment in which a patient's T-cells are changed in the laboratory to attack cancer cells. T-cells are taken from a patient's blood and modified to produce special receptors on their surface called chimeric antigen receptors (CARs).
  • Relapsed: When cancer returns after a period of improvement.
  • Refractory: When cancer does not respond to treatment or stops responding after initial improvement.
  • Minimal Residual Disease (MRD): Small numbers of cancer cells that remain in the body during or after treatment. These cells are often too few to be detected by standard tests.
  • Apheresis: A medical procedure in which blood is taken from a person and separated into its components, some of which are kept and others returned to the body.
  • Complete Remission (CR): When there is no evidence of disease and blood counts have returned to normal.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug or treatment that are severe enough to prevent an increase in dose or level of that treatment.

References

  1. http://clinicaltrials.eu/trial/study-of-cd7-cart01-cyclophosphamide-and-fludarabine-phosphate-for-children-and-young-adults-with-relapsed-or-refractory-t-cell-acute-lymphoblastic-leukemia-lymphoma/